NVAX

Business Context and Reporting Period

Company: Novavax, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: Novavax is a clinical-stage biopharmaceutical company developing recombinant vaccines using a virus-like-particle (VLP) platform. Key product candidates include vaccines for pandemic influenza (H1N1, H5N1), seasonal influenza, Respiratory Syncytial Virus (RSV), and Varicella Zoster Virus (VZV). The company operates with a joint venture in India (CPL Biologicals) and relies on government contracts and equity financing.

Key Financial Metrics

Note: Revenue consists of services performed under contracts with U.S. government agencies. The company has no commercial product sales.

Material Changes vs. Prior Period

• Revenue Increase: Revenue rose to $110,000 from $21,000 in Q1 2009, driven by government contract services.
• Net Loss Expansion: Net loss increased by $3.1 million (37%) to $11.4 million. This was primarily due to a $4.8 million increase in R&D expenses to support H1N1 and seasonal influenza clinical trials.
• R&D Spending Surge: R&D expenses more than doubled (112% increase) due to higher outside testing costs, including outsourced clinical trials and consulting.
• Investment Portfolio Shift: Short-term investments increased significantly from $4.2 million to $18.3 million as the company deployed cash into commercial paper and corporate notes to improve returns.
• Cash Burn: Net cash used in operating activities increased to $9.4 million from $6.7 million. Total cash and equivalents decreased by $24.2 million during the quarter due to operating losses and investment purchases.
• Interest Expense Reduction: Interest expense dropped to $2,000 from $437,000 following the repayment of convertible notes in 2009.

Outlook, Risks, and Management Commentary

• Liquidity Position: Management believes current cash ($14.6M) and short-term investments ($18.3M), combined with an "At the Market" sales agreement allowing up to $50M in stock sales, are sufficient to fund operations for at least the next 12 months.
• Clinical Progress:
  • H1N1: Completed enrollment for a two-stage trial in Mexico (3,500+ subjects); primary safety results expected later in 2010.
  • Seasonal Flu: Phase II results in healthy adults and older adults (60+) showed the vaccine was safe and immunogenic.
  • RSV/VZV: Pre-clinical studies completed; IND application for RSV expected in 2010.
• Government Contract: The company's proposal for a BARDA (Biomedical Advanced Research and Development Authority) contract for pandemic preparedness is in the "competitive range," but no award is guaranteed.
• Future Financing: Additional capital will be required for commercialization. Future equity offerings will likely be dilutive. Failure to secure funding could force delays in R&D or downsizing.
• Legal Proceedings: The company has sued two former directors (Mitch Kelly and Denis O'Donnell) for the collection of $1.572 million in defaulted notes.
• Contingencies: Potential milestone payment of $4 million to Wyeth Holdings Corporation may be due within 12 months if clinical/commercial milestones are met.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $32.9M total liquid assets against the projected burn rate of ~$9.4M per quarter.
• BARDA Contract Status: Monitor the outcome of the competitive range determination for the HHS BARDA contract, which is critical for non-dilutive funding.
• Clinical Trial Results: Await the release of primary safety results from the Mexico H1N1 trial later in 2010.
• Equity Dilution: Track the utilization of the new "At the Market" sales agreement with McNicoll, Lewis & Vlak LLC.
• Legal Recovery: Assess the likelihood of recovering the $1.572 million owed by former directors.
• Wyeth Milestones: Confirm whether the $4 million milestone payment to Wyeth will be triggered in the next 12 months.